Cationic Lipid RNA Lipoplex Formulation for Room-Temperature Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mRNA vaccines face challenges with poor stability at room temperature, high storage and transportation costs due to ultra-low temperature requirements, and potential toxicity from high N/P lipid ratios, necessitating a more stable and safe delivery system for nucleic acids.
Innovation Solution
A cationic lipid-based composition comprising N-oleyl, N-octadecyl, N, N dihydroxyethyl ammonium chloride, cholesterol, and phospholipids like DOPE, formulated with a low N/P ratio, forms a stable lipid/RNA complex (lipoplex) that maintains efficacy at room temperature and minimizes toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If higher concentrations of therapeutic agents are used to overcome cell entry restrictions, then delivery efficiency is improved, but toxic effects and side effects increase
Solution Approach 1:
The patent employs cationic lipids as intermediary carrier molecules that mediate the delivery of nucleic acid therapeutics into cells. These lipids form complexes with nucleic acids, facilitating cell entry while allowing the use of lower, safer concentrations of the therapeutic agent compared to direct delivery methods.
Solution Approach 2:
The patent optimizes the N/P ratio (ratio of cationic lipid to nucleic acid phosphate groups) as a critical parameter. By controlling this ratio within specific ranges (e.g., 1:0.5 to 10:1), the system achieves efficient cellular uptake and transfection while minimizing toxicity, thus resolving the contradiction between delivery efficiency and harmful effects.
2Productivity
If existing lipid-based delivery systems are used, then nucleic acid delivery is achieved, but stability at room temperature is poor requiring ultra-low temperature storage
Solution Approach 1:
The patent employs composite lipid formulations combining multiple lipid components with different properties. This composite approach creates lipoplexes that maintain structural integrity and nucleic acid complexation stability at room temperature, eliminating the need for ultra-low temperature storage while preserving delivery capability.
Solution Approach 2:
The patent modifies key parameters of the lipid formulation including the N/P ratio, lipid composition ratios, and molecular weight characteristics to enhance thermal stability. These parameter optimizations enable the delivery system to remain stable at ambient temperatures without compromising its nucleic acid delivery function.
3Productivity
If existing lipid formulations are used, then nucleic acid complexation is achieved, but storage and transportation costs are high due to ultra-low temperature requirements
Solution Approach 1:
The patent optimizes formulation parameters including N/P ratio and lipid composition to achieve stable nucleic acid complexation at room temperature. This eliminates the need for energy-intensive ultra-low temperature storage and transportation infrastructure, significantly reducing storage costs while maintaining complexation ability.
Solution Approach 2:
The patent develops a stable lipoplex formulation that can be stored at ambient temperatures without requiring expensive cold chain infrastructure. This approach replaces expensive long-term ultra-low temperature storage with affordable room temperature storage, making the delivery system more economically viable for widespread distribution.
4Productivity
If high N/P lipid ratios are used, then delivery effectiveness is improved, but lipid-mediated toxicity increases
Solution Approach 1:
The patent identifies and optimizes the N/P ratio parameter to a specific optimal range (e.g., 1:0.5 to 10:1) where delivery effectiveness is maximized while lipid-mediated toxicity is minimized. This parameter optimization resolves the contradiction by finding the sweet spot between therapeutic efficacy and safety.
Solution Approach 2:
The patent uses composite lipid formulations that combine cationic lipids with neutral or zwitterionic lipids in specific ratios. This composite approach allows for effective nucleic acid complexation and cellular uptake (delivery effectiveness) while the neutral/zwitterionic components mitigate the toxicity associated with high concentrations of cationic lipids alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides a stable, low-cost, and safe delivery system for nucleic acids, enabling efficient transfection and reducing lipid-mediated toxicity, with a shelf life of at least 30 days at room temperature.
Implementation Method 1
The lipids spontaneously form aggregates and carry surface positive charges that make electrostatic complexation with nucleic acids, which are negatively charged
Data Source
AI summary
The present invention discloses a cationic lipid-based formulation for in vivo delivery of nucleic acid. The present invention describes the development of a lipid system that can induce efficient non-viral delivery of nucleic acid. especially RNA. for the purpose of efficient nucleic acid transfection toward eliciting vaccination in vivo. Present invention provides a lipid/RNA complex (lipoplex) formulation having sufficiently long shelf life that performs without any compromise in its transfection output. The present invention further provides cationic lipid-based formulations for RNA delivery with maximum nucleic acid complexation ability and with comparatively lesser amount of cationic lipid having higher stability.